At the inaugural ACCC Leadership Summit, C-suite executives and senior-level decision makers in oncology convened for strategic dialogue, engaging panel discussions, and peer-to-peer exchange focused on the most pressing issues in cancer care today. In this episode, CANCER BUZZ speaks with Michele LeSueur, DBA, vice president of Sales and Marketing at Johnson & Johnson, about her key takeaways as a member of the final panel of the Summit: Strategic Partnerships: Creating a Thriving Innovation Oncology Ecosystem. Across the diverse panel of stakeholders, one theme consistently rang true: Innovation is happening very quickly in oncology, but the gap continues to widen between the inception and the implementation of these ideas into day-to-day patient care. Lesueur also comments on the importance of industry partners listening and understanding where friction might occur when launching a new treatment or delivery system.
"It's not just about continuously generating breakthrough science or breakthrough treatment. That's only going to take us so far. We have to think about how to actually incorporate that and get it to the patients.” – Michele LeSueur, DBA
Guest:
Michele LeSueur, DBA
Vice President of Sales and Marketing
Johnson & Johnson
Resources:
This podcast was made possible with support from Johnson & Johnson.
The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Cancer Care Centers.
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
